Abstract:A subset of cardiomyocytes acquires a senescence‐associated secretory phenotype (SASP) when subjected to doxorubicin (Dox). SASP cardiomyocytes affect healthy non‐senescent cardiomyocytes, rendering them senescent through delivery of exosomes. Clearance of senescent cardiomyocytes using the Bcl‐2 inhibitor ABT‐199 alleviates senescence of cardiomyocytes and prevents chemotherapy‐related cardiotoxicity. Our findings suggest that SASP senescent cardiomyocytes are a significant component of the pathogenesis of Dox‐related cardiotoxicity and could be a new therapeutic target for Dox‐induced cardiac injury. Doxorubicin (Dox), an anthracycline antibiotic, is widely used in cancer treatment. Although its antitumor efficacy appears significant, its clinical use is greatly restricted by its induction of cardiotoxicity. Cardiac senescence drives the Dox‐induced cardiotoxicity, but whether diminishing these senescent cardiomyocytes could alleviate the cardiotoxicity remains unclear. Here, we assessed whether senescent cardiomyocytes have a senescence‐associated secretory phenotype (SASP) that affects healthy non‐senescent cardiomyocytes, rendering them senescent via the delivery of exosomes. Additionally, we explored whether targeting SASP senescent cardiomyocytes using a Bcl‐2 inhibitor could alleviate cardiotoxicity. Cardiac damage was induced in a mouse model of continuous Dox treatment in vivo, and cardiomyocytes in vitro. Immunofluorescence of the senescence markers of Cdkn2a, Cdkn1a and γ‐H2A.X was used to assess the SASP in the Dox‐treated heart. To explore the molecular mechanisms involved, the Bcl‐2 inhibitor ABT‐199 was employed to eliminate SASP senescent cardiomyocytes. We show that the cardiomyocytes acquire a SASP during Dox treatment. The senescent cardiomyocytes upregulated Bcl‐2, although treatment of mice with ABT‐199 selectively eliminated SASP senescent cardiomyocytes involved in Dox‐induced cardiotoxicity, thus leading to partial alleviation of Dox‐induced cardiotoxicity. Moreover, we concluded that SASP factors secreted by senescent cardiomyocytes induced by Dox renders otherwise healthy cardiomyocytes senescent through exosome delivery. Our findings suggest that SASP senescent cardiomyocytes are a significant component of the pathogenesis of Dox‐dependent cardiotoxicity and indicate that targeting the clearance of SASP senescent cardiomyocytes could be a new therapeutic approach for Dox‐induced cardiac injury.

Endogenous Hydrogen Sulfide Persulfidates Caspase-3 at Cysteine 163 to Inhibit Doxorubicin-Induced Cardiomyocyte Apoptosis

Hydrogen sulfide protects cardiomyocytes from doxorubicin-induced ferroptosis through the SLC7A11/GSH/GPx4 pathway by Keap1 S-sulfhydration and Nrf2 activation

Exogenous Hydrogen Sulfide Protects Against Doxorubicin-Induced Inflammation and Cytotoxicity by Inhibiting P38mapk/nf&#954;b Pathway in H9c2 Cardiac Cells

Gp130-mediated STAT3 Activation by S-propargyl-cysteine, an Endogenous Hydrogen Sulfide Initiator, Prevents Doxorubicin-Induced Cardiotoxicity

Sulphenylation of CypD at Cysteine 104: A Novel Mechanism by Which SO2 Inhibits Cardiomyocyte Apoptosis

Sodium thiosulfate prevents doxorubicin-induced DNA damage and apoptosis in cardiomyocytes in mice

Hydrogen Sulfide Protects Against Apoptosis under Oxidative Stress Through Sirt1 Pathway in H9c2 Cardiomyocytes

Hydrogen Sulfide‐induced Apoptosis of Human Aorta Smooth Muscle Cells Via the Activation of Mitogen‐activated Protein Kinases and Caspase‐3

Saikosaponin D Alleviates DOX-induced Cardiac Injury In Vivo and In Vitro

Histone Demethylase JMJD3 Mediated Doxorubicin-Induced Cardiomyopathy by Suppressing SESN2 Expression

SS-31 Attenuates Doxorubicin-induced Cardiomyoblast H9C2 Cell Senescence

Hydroethanolic extract of Cirsium setidens ameliorates doxorubicin-induced cardiotoxicity by AMPK-PGC-1α-SOD-mediated mitochondrial protection

Peptide Szeto‑Schiller 31 Ameliorates Doxorubicin‑induced Cardiotoxicity by Inhibiting the Activation of the P38 MAPK Signaling Pathway.

S-diclofenac Protects Against Doxorubicin-Induced Cardiomyopathy in Mice Via Ameliorating Cardiac Gap Junction Remodeling

USP14 modulates cell pyroptosis and ameliorates doxorubicin-induced cardiotoxicity by deubiquitinating and stabilizing SIRT3

Depletion of SASP senescent cardiomyocytes with senolytic drugs confers therapeutic effects in doxorubicin‐related cardiotoxicity

Pro‐apoptotic Effect of Endogenous H2S on Human Aorta Smooth Muscle Cells

Efflux Inhibition by H2S Confers Sensitivity to Doxorubicin-Induced Cell Death in Liver Cancer Cells.

AP39, a novel mitochondria-targeted hydrogen sulfide donor ameliorates doxorubicin-induced cardiotoxicity by regulating the AMPK/UCP2 pathway

Sphingosylphosphorylcholine ameliorates doxorubicin-induced cardiotoxicity in zebrafish and H9c2 cells by reducing excessive mitophagy and mitochondrial dysfunction

Mitochondrial Sirtuins and Doxorubicin-induced Cardiotoxicity